003020 立方制药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.9329.3159.38214.32215.033
总资产报酬率 ROA (%)1.3486.3886.3369.84411.025
投入资产回报率 ROIC (%)1.8388.9018.99112.95213.104

边际利润分析
销售毛利率 (%)65.86064.55169.16151.48337.385
营业利润率 (%)11.70511.72011.70513.4309.307
息税前利润/营业总收入 (%)11.62011.73811.30013.3699.160
净利润/营业总收入 (%)9.87410.52610.04212.3048.112

收益指标分析
经营活动净收益/利润总额(%)97.12778.33994.58884.75884.453
价值变动净收益/利润总额(%)-1.57615.3297.56810.80013.449
营业外收支净额/利润总额(%)-1.182-0.171-3.4450.834-0.097

偿债能力分析
流动比率 (X)2.2812.2592.0372.1212.333
速动比率 (X)1.8611.8671.6581.6731.752
资产负债率 (%)25.02624.52626.04024.56830.241
带息债务/全部投入资本 (%)2.8831.3182.9881.49314.462
股东权益/带息债务 (%)3,277.4627,272.9683,188.4956,459.033584.027
股东权益/负债合计 (%)278.078285.235258.085276.234230.675
利息保障倍数 (X)225.757311.052-758.353-77.149-66.620

营运能力分析
应收账款周转天数 (天)111.80295.16274.38054.86542.121
存货周转天数 (天)159.506138.881178.119118.02461.367